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Abstract
Background: Intracranial hypertension (ICH) is a major cause of death after traumatic brain injury (TBI). Continuous
hyperosmolar therapy (CHT) has been proposed for the treatment of ICH, but its effectiveness is controversial. We
compared the mortality and outcomes in patients with TBI with ICH treated or not with CHT.
Methods: We included patients with TBI (Glasgow Coma Scale ≤ 12 and trauma-associated lesion on brain
computed tomography (CT) scan) from the databases of the prospective multicentre trials Corti-TC, BI-VILI and
ATLANREA. CHT consisted of an intravenous infusion of NaCl 20% for 24 hours or more. The primary outcome was
the risk of survival at day 90, adjusted for predefined covariates and baseline differences, allowing us to reduce the
bias resulting from confounding factors in observational studies. A systematic review was conducted including
studies published from 1966 to December 2016.
Results: Among the 1086 included patients, 545 (51.7%) developed ICH (143 treated and 402 not treated with
CHT). In patients with ICH, the relative risk of survival at day 90 with CHT was 1.43 (95% CI, 0.99–2.06, p = 0.05). The
adjusted hazard ratio for survival was 1.74 (95% CI, 1.36–2.23, p < 0.001) in propensity-score-adjusted analysis. At day
90, favourable outcomes (Glasgow Outcome Scale 4–5) occurred in 45.2% of treated patients with ICH and in 35.8%
of patients with ICH not treated with CHT (p = 0.06). A review of the literature including 1304 patients from eight
studies suggests that CHT is associated with a reduction of in-ICU mortality (intervention, 112/474 deaths (23.6%) vs.
control, 244/781 deaths (31.2%); OR 1.42 (95% CI, 1.04–1.95), p = 0.03, I2 = 15%).
Conclusions: CHT for the treatment of posttraumatic ICH was associated with improved adjusted 90-day survival.
This result was strengthened by a review of the literature.
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Background
Severe trauma is responsible of more than 5 million
deaths every year worldwide and this incidence is ex-
pected to increase in the coming decades [1]. Traumatic
brain injury (TBI) is the most severe condition observed
in trauma patients, given that nearly 33% of patients
with TBI die in hospital and another 33% have poor
neurological recovery [2]. The sequelae and changes in
quality of life observed after severe TBI are associated
with an excess risk of death long after hospital discharge
[3]. Therapies are therefore urgently needed to decrease
mortality and the tremendous medical costs of TBI [4].
Prevention and treatment of intra-cranial hypertension
(ICH) are the cornerstones of treatment for patients
with TBI in intensive care units (ICUs), as uncontrolled
ICH worsens brain damage and remains the most com-
mon cause of death after severe TBI [5]. Several strat-
egies are recommended for the treatment of ICH but
few have been demonstrated to improve long-term out-
comes [6]. After sedation and head positioning, boluses
of hyperosmolar therapy are frequently the second-tier
strategy of ICH treatment, but the induced reduction in
intracranial pressure (ICP) is transient and a rebound of
ICH is frequently observed after a few hours [7, 8].
Continuous infusion of hyperosmolar therapy has there-
fore been proposed for the treatment of patients with
severe brain injury, but its effects on survival and out-
comes have been disappointing [9].
A recent retrospective study performed at our institu-
tion suggested that ICP was better controlled in patients
with TBI with ICH refractory to barbiturates when using
continuous hyperosmolar therapy [10]. We therefore
aimed to investigate the effects of early administration of
continuous hyperosmolar therapy in patients with TBI
with ICH on mortality and long-term outcomes. We used
data collected in three prospective trials involving patients
with TBI to compare mortality (primary objective) and
long-term outcomes (secondary objective) in patients with
TBI with ICH treated or not with early continuous hyper-
osmolar therapy (CHT). Given the observational design of
the study, we planned a priori to use a propensity adjust-
ment for the comparison of the primary outcome between
treated and untreated patients because it enabled us to re-
duce the bias resulting from confounding factors in obser-
vational studies. Finally, we conducted a systematic review
incorporating the findings of this trial.
Methods
Ethics approval
The study protocol of this sub-study of three prospective
trials was approved by an institutional review board
(Comité d'Éthique de la Recherche en Anesthésie-Réani-
mation, CERAR#2016-01-03). Informed consent was
waived owing to the non-interventional design of this
study and because relatives and patients provided in-
formed consent for the collection of the medical data in
the original studies.
Study design
Prospectively collected individual patient data from three
studies were pooled together. The CORTI-TC trial was a
multicentre (19 ICUs), randomised, double-blind, placebo-
controlled trial of hydrocortisone and fludrocortisone in
patients with TBI (NCT01093261) [11]. The BI-VILI study
(NCT01885507) was a multicentre (20 ICUs) before-after
evaluation of a quality improvement project, aiming to
promote protective mechanical ventilation (association of
low tidal volume and moderate positive end-expiratory
pressure) in brain-injured patients [12]. The ATLAN-
REA cohort (NCT02426255) was a prospective non-
interventional multicentre (four ICUs) follow up of
brain-injured patients requiring more than 24 hours of
mechanical ventilation [13]. All the centres are experts
in the care of patients with TBI and each centre receive
more than 50 severe patients with TBI per year.
Population
We included all patients with TBI from 15 to 75 years of
age with a duration of mechanical ventilation ≥ 24 hours.
Inclusion criteria were patients with moderate (Glasgow
Coma Scale (GCS) score 9–12) to severe (GCS score 3–8)
traumatic brain injury with one or more acute processes
related to trauma on cerebral computed tomography (CT)
imaging. Exclusion criteria were non-traumatic brain in-
jury or an early decision to withdraw care (during the first
24 hours in the ICU).
Definition of intra-cranial hypertension
ICH was defined as one or more in-ICU episodes of ICP
higher than 20 mmHg [6] with a duration that required
specific therapeutic intervention.
General care of brain-injured patients (stage 1 treatment)
Investigators followed the brain trauma foundation
guidelines for TBI resuscitation [6], except for one
centre, which used CHT as a first-line treatment for
ICH. All patients were sedated with a continuous
intravenous infusion of hypnotic and morphinic agents
and were mechanically ventilated. Sedated patients
were kept in a semi-recumbent position unless there
were contraindications to this. Secondary brain injuries
were prevented by keeping body temperature between
36.0 °C and 37.0 °C, ensuring normoglycaemia and
normocapnia and avoiding hypoxaemia (stage 1 treat-
ment, Additional file 1: Figure S1). Natraemia was
tested in blood twice a day in the control group (or
more frequently in the case of abnormalities), and
normal natraemia (138–145 mmol/L) was maintained
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in the absence of ICH (Additional file 1: Figure S1).
Intracranial pressure was monitored with an intra-
parenchymal probe (Codman, Johnson and Johnson
Company, Raynham, MA, USA.) placed in the most af-
fected side of the brain as identified on CT. External-
ventricular drainage was performed in the case of
hydrocephalus.
Treatment of intracranial hypertension (stage 2 and 3
treatments)
A bolus of hyperosmolar therapy (mannitol 0.25 to
1 g/kg body weight [6] or hypertonic saline solution,
250 mOsm dose [7]) was routinely used as first-line
treatment to control episodes of ICH. Boluses of
hyperosmolar therapy were repeated in the case of
poor ICP control (ICP > 20 mmHg) and when plasma
osmolality remained < 320 mosm/L. When control of
ICH was poor despite optimized hyperosmolar therapy
(ICP > 20 mmHg), barbiturate (sodium thiopental with a
loading dose of 2–3 mg.kg-1 followed by a continuous
infusion of 2–3 mg.kg-1.h-1), moderate hypothermia
(33–35 °C), moderate hypocapnia (partial arterial pres-
sure of carbon dioxide (PaCO2) 32–36 mmHg) and de-
compressive craniectomy were used according to each
centre's protocols and following international recom-
mendations [6]. The control group received stage 1 and
2 treatments but without continuous hyperosmolar
therapy (Additional file 1: Figure S1).
Early continuous hypertonic saline therapy
In one of the participating centres, continuous hyperos-
molar saline therapy was infused as the first-line treat-
ment of intracranial hypertension (i.e. when stage 1
treatments had failed). Continuous hypertonic saline
therapy consisted of a 1-hour bolus of hypertonic saline
solution (20% hypertonic saline solution) followed by an
intravenous infusion for a duration of 24 hours or more,
prolonged as long as required to control ICP. Continu-
ous hyperosmolar therapy was routinely adapted to the
blood level of sodium measured before the first bolus,
then every 4–8 hours during the treatment. As previ-
ously described (Additional file 2: Figure S2 and [10]),
the attending physician set an increasing target of
natraemia that could be increased by increments of
5 mmol/L (up to 155 mmol/L) according to the evolu-
tion of ICP. In the case of poor control of ICP, second-
step treatments were administered. For treatment
discontinuation, the target natraemia was gradually
decreased to 145 mmol/L (by decrements of 5 mmol/L).
Data handling
For each of the included studies, data were collected
prospectively using the specific websites of each trial.
Detailed information explaining instructions for data
collection and definitions for outcomes were made avail-
able to all investigators before data collection started.
For quality assurance purposes, data were electronically
checked for uniformity and completeness. Errors or un-
filled fields generated queries that were returned to each
centre for correction. Missing data are described in the
“Results” section.
Endpoints
The primary endpoint was the risk of survival at day 90
in patients receiving or not receiving CHT for the treat-
ment of ICH. Because we anticipated imbalances in key
risk factors at baseline among patients developing ICH
treated or not with CHT, the primary outcome was ad-
justed for such imbalances. We also calculated the crude
mortality at day 90.
The secondary endpoint was the dichotomized Glas-
gow Outcome Scale (GOS) at day 90 (GOS 1–3 vs. 4–5).
Safety was investigated through the time course of the
blood level of sodium, urea and creatinine in the first
5 days of therapy and the rate of central pontine
myelinolysis.
Statistical analysis
First, in order to identify baseline differences associated
with CHT, univariate analysis was applied using the chi-
square test for categorical data, Student's t test or
Wilcoxon test was used for continuous data and the log-
rank test for censored data.
For primary analysis, as we previously described [14],
propensity score analysis (based on inverse probability
weighting) was applied to estimated 90-day survival. The
propensity score included predefined covariates (CT
classification, age, GCS, non-reactive pupil, hypoxaemia
and interventional study arms) [15] and covariates iden-
tified by univariate analysis (Cox models were estimated;
if p values were < 0.20 then the variable was selected,
then a backward selection procedure was applied to keep
only variables that were significant at the 5% level).
As for sensitivity analysis, we also calculated the non-
adjusted hazard ratio (univariate Cox model) and we
produced a multivariate Cox model (adjusted on covar-
iates included in the propensity score). The propor-
tional hazards assumption was inspected using
Schoenfeld residuals.
Continuous data were expressed as mean ± standard
deviation for parametric data and as median (25th to
75th percentiles) for non-parametric data. Categorical
data were expressed as number and percentage. A two-
sided p value <0.05 was considered statistically signifi-
cant. Statistical analysis was performed with SAS
statistical software (SAS 9.3 Institute, Cary, NC, USA).
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Systematic review
Meta-analyses and systematic reviews of observational
studies (MOOSE) guidelines were followed in the design
and implementation of this systematic review of the lit-
erature. We attempted to identify all relevant studies
published in English regardless of publication status
(published or in press). We considered abstracts pre-
sented at scientific meetings < 3 years ago (Society of
Critical Care Medicine, European Society of Intensive
Care Medicine, Societe Française d’Anesthesie-Reanima-
tion, Societe de Reanimation de Langue Française).
PubMed® (MEDLINE/Index Medicus) and the Cochrane
Controlled Trials Register were searched for studies
published from January 1969 until 31 December 2016.
The Medical Subject Heading terms used for the search
were “Intracranial Hypertension/drug therapy” OR
“Sodium Lactate/therapeutic use” OR “Brain Edema/
drug therapy” AND “Saline Solution, Hypertonic/admin-
istration & dosage” with the limit “human”. The “related
articles” hyperlinks in Medline were explored for add-
itional references. The reference lists of all selected trials
and previously published meta-analyses were checked
for additional references. The authors selected all studies
that evaluated CHT in brain-injured patients. We se-
lected the following key outcomes: number of in-ICU
deaths, rate of ICH and rate of severe hypernatraemia
(Na+ > 160 mmol/L). Treatment effects were reported as
RRs with 95% confidence intervals for discontinuous
outcomes. Analyses were performed using RevMan®
version 5.3 using fixed-effects models with random-
effects models for comparison (see Additional file 3:
supplemental methods).
Results
Among the 1086 included patients, 545 (50.2%) devel-
oped ICH, among whom 143 (26.2%) received CHT
(Fig. 1). The demographic characteristics and outcomes
of patients with TBI without ICH, and patients with ICH
treated or not with CHT are described in Table 1. Con-
tinuous hyperosmolar therapy was initiated for a median
duration of 5 (3–8) days.
At day 90, 475 patients (87.8%) without ICH were alive
compared with 265 (65.9%) patients with ICH not
treated with CHT (p < 0.001) and 106 patients (74.1%)
with ICH and treated with CHT (p = 0.001).
Effects of continuous hyperosmolar therapy in patients
with traumatic brain injury with intracranial hypertension
Blood levels of sodium were higher in patients with TBI
with ICH than in patients without ICH (p < 0.001, Fig. 2a).
Blood levels of sodium were higher in patients with TBI
with ICH treated with CHT than in those not treated with
CHT (p < 0.001, Fig. 2a). ICP levels were lower in patients
with TBI with ICH treated with CHT than in those treated
with standard treatment (Fig. 2b). Patients with TBI
treated with CHT less frequently required the application
of moderate hypocapnia (p = 0.0002) or decompressive
craniectomy (p = 0.002) than patients whose care com-
plied with the recommendations (Table 1).
Primary outcome
In the population of patients with TBI with ICH, the crude
HR for mortality at day 90 with CHT was 1.43 (95% CI,
0.99 - 2.06, p = 0.05, Fig. 3a). In propensity score analysis
adjusted for predefined criteria (CT classification, age,
Fig. 1 Flow chart. GOS Glasgow Outcome Scale
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Table 1 Comparison of patients with intracranial hypertension treated or not with continuous hyperosmolar therapy (CHT)
Characteristics Without intracranial
hypertension
With intracranial hypertension
Not treated with CHT Treated with CHT P valuesa
Number of patients 541 402 143
Age, years 42 (25–58) 38 (24–53) 37 (21–57) 0.74
Male 430 (79.5) 323 (80.4) 114 (79.7) 0.87
Injury Severity Score 25 (16–34) 25 (17–33) 27 (25–41) < 0.0001
Glasgow Coma Scale 6 (4–8) 5 (3–7) 6 (4–8) 0.0002
One or two non-reactive pupils, yes 98 (26) 102 (38.4) 45 (31.5) 0.17
Hypoxaemia, yes 62 (11.5) 79 (19.7) 41 (28.7) 0.03
Hypotension, yes 186 (34.4) 145 (36.1) 46 (32.2) 0.40
CT classification 0.002
I 20 (3.8) 11(2.8) 1 (0.7)
II 174 (32.9) 94 (23.7) 43 (30.1)
III 28 (5.3) 35 (8.8) 15 (10.5)
IV 20 (3.8) 24 (6.1) 21 (14.7)
V 169 (32.0) 165 (41.6) 40 (28.0)
VI 118 (22.3) 68 (17.1) 23 (16.1)
Corti-TC trial – inclusion, yes 161 (29.8) 134 (33.3) 31 (21.7) 0.009
Corti-TC trial – steroids, yes 85 (15.7) 63 (15.7) 16 (11.2) 0.191
BI-VILI trial – inclusion, yes 179 (33.1) 155 (38.6) 0 (0.0) < .0001
BI-VILI trial – fully compliant, yes 1 (1.7) 0 (0.0) 0 (0.0) -
Management of intracranial hypertension, yes
Hyperosmolar therapy (bolus) NA 309 (76.9) 82 (57.3) < 0.0001
Barbiturate NA 192 (47.8) 78 (54.6) 0.16
Hypothermia NA 111 (27.6) 62 (43.4) 0.0005
Moderate hypocapnia NA 61 (15.2) 5 (3.5) 0.0002
Decompressive craniectomy NA 87 (21.6) 14 (9.8) 0.002
Duration of invasive ventilation, days 10 (5–19) 18 (12–27) 18 (13–26) 0.79*
ICU length of stay, days 15 (9–25) 24 (16–34) 25 (18–35) 0.93*
Decision to withdraw care in ICU, yesb 38 (10.0) 46 (17.2) 23 (16.1) 0.77
Survival
In ICU 489 (90.4) 269 (66.9) 106 (74.1) 0.11
At day 90 475 (87.8) 265 (65.9) 106 (74.1) 0.07
GOS at day 90c 0.01
Dead 66 (17.0) 137 (42.6) 37 (26.1)
Vegetative 6 (1.5) 10 (3.1) 5 (3.5)
Severe disability 84 (21.6) 60 (18.6) 36 (25.4)
Moderate disability 87 (22.4) 52 (16.2) 34 (23.9)
Good recovery 146 (37.5) 63 (19.6) 30 (21.3)
Moderate to good recovery (GOS 4–5) 133 (59.9) 115 (35.8) 64 (45.2) 0.06
Results express as median (25th–75th percentile) or number (percentage)
Computed tomography (CT) classification: I, no visible intracranial pathology on CT scan; II, midline shift 0–5 mm; III, cisterns compressed or absent with midline
shift 0–5 mm; IV, midline shift > 5 mm; V, any lesion surgically evacuated; VI, high-density or mixed-density lesion > 25 mm, not surgically evacuated
ICU Intensive Care Unit, GOS Glasgow outcome scale
aP values for comparisons between patients with intracranial hypertension treated or not with continuous hyperosmolar therapy
bAvailable in 410 patients
cAvailable in 322 patients (80%) untreated with continuous hyperosmolar therapy and in 142 patients (99%) treated with continuous hyperosmolar therapy
*Log-rank test
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ba
Fig. 2 Time course of the blood levels of sodium (a) and of intracranial pressure (b) in patients treated or not with continuous hyperosmolar
therapy. ICH intracranial hypertension
b
a
Fig. 3 Comparison of 90-day outcomes in patients with traumatic brain injury (TBI) with intracranial hypertension (ICH) treated or not with
continuous hyperosmolar therapy. a Cumulative incidence curves for survival at day 90. b Glasgow Outcome Scale (GOS) at day 90 in patients
with TBI with ICH treated or not with continuous hyperosmolar therapy
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GCS, non-reactive pupil, hypoxaemia and interventional
study arms) [15] and baseline imbalances (Table 1), the
adjusted HR for survival at day 90 was 1.74 (95% CI,
1.36 - 2.23, p < 0.001) (Fig. 3a). Sensitivity analysis to
evaluate the robustness of this adjustment was performed,
with multivariate analysis investigating the factors inde-
pendently associated with survival at day 90 (Additional
file 4: Table S1). In multivariate analysis, the adjusted HR
for survival with early CHT was 1.98 (95% CI, 1.3 - 32.96,
p < 0.001; Additional file 4: Table S1).
At day 90, the GOS distribution differed between the
treated and untreated patients (p = 0.01, Fig. 3b).
Favourable outcomes (pre-specified as moderate to good
recovery on the GOS) occurred in 45.2% of patients with
ICH treated with early CHT and in 35.8% of patients
with ICH not treated with CHT (p = 0.06).
Tolerance of continuous hyperosmolar therapy
The main side effect observed in patients treated with
continuous hyperosmolar therapy was moderate hyperna-
traemia (145–159 mmol/L, Additional file 2: Figure S2A).
Severe hypernatremia (≥ 160 mmol/L) was more fre-
quent in treated patients (n = 13, 9.1%) vs. untreated
patients (n = 9, 2.2%, p < 0.001). The time course of
serum urea and of creatinine did not alter significantly
during CHT (Additional file 5: Figure S3). No case of
central pontine myelinolysis was recorded.
Systematic review of the literature
Given the potential bias of this observational study, not-
ably a potential centre-effect, the reported increase in the
risk of survival associated with CHT could have been
underestimated or overestimated. We therefore performed
a review of the literature to compare our estimation of the
effect of the treatment on survival with the effects that
have been reported in previous studies.
Systematic review of the literature identified eight
studies, including the current results that involved 1304
participants, with seven trials including 1255 partici-
pants providing in-hospital mortality data (Additional
file 6: Figure S4). Descriptions of the studies are
provided in Additional files 7 and 8: Tables S2 and S3.
Mortality was less frequent in patients treated with CHT
(intervention 112/474 (23.6%) vs. control 244/781
(31.2%); OR 1.42, 95% CI, 1.04–1.95), p = 0.03, I2 = 15%,
Fig. 4). In sub-group analyses, the OR for survival with
treatment changed little between the randomised clinical
trials and the observational studies (OR 1.71 (95% CI,
0.55–5.26) vs. 1.39 (95% CI 0.95–2.05), respectively).
Discussion
In this large prospective multicentre cohort, the early
use of CHT in patients with TBI with ICH was safe and
was independently associated with survival at day 90.
Moreover, after incorporating the present results in a re-
view of the literature, we confirmed that CHT was asso-
ciated with decreased mortality. In the review of the
literature, we identified low heterogeneity between the
risk ratio (RR) for survival, suggesting that the effect of
CHT is little altered by a centre-effect and could be ex-
trapolated to daily practice.
ICH increases brain damage and its treatment remains
critical for improving outcomes. The beneficial effects of
hyperosmolar therapy have mainly been described for
clinical variables such as control of ICP and for a few
hours after administration of a bolus [8, 16, 17]. Our re-
sults show that ICP was lower and that surrogate
markers of the course of ICH (boluses of hyperosmolar
Fig. 4 Number of patients deceased on day 28 or hospital discharge in the review of literature. M-H Mantel-Haenszel
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therapy, moderate hypocapnia or performance of cra-
niectomy) are less frequently used in patients treated
with CHT. When hyperventilation is recommended as a
temporizing measure for the reduction of elevated ICP
[6, 18], there are fewer reported episodes of hyperventi-
lation therapy or hypothermia. This could also be con-
sidered as a beneficial effect of CHT. Given that we have
previously reported no rebound of ICH during hyperos-
molar therapy tapering [10], these results suggest that
CHT provides prolonged control of ICP after acute brain
injury. However, the protective effects observed with the
use of CHT can be mediated by other mechanisms than
ICP control [16, 19]. For example, CHT reduces the risk
of hypovolaemia, which is associated with secondary
brain injuries [20].
Before implementing CHT in clinical practice, it is
critical to determine the timing of administration that
will be the most efficient to enhance outcomes. In the
COBI cohort study, we identified association between
survival and treatment when CHT was used as a first-
step treatment for ICH. Continuous hyperosmolar ther-
apy has also been proposed as preventive treatment in
brain-injured patients at risk of ICH [21–23]. Interest-
ingly, our review of the literature provided evidence that
CHT reduces the risk of ICH when applied as preventive
therapy and we found little difference in the reduction
of the risk of death between preventive and curative
CHT. Taken altogether, these results suggest that CHT
could be used early after TBI in patients deemed at high
risk of developing ICH [21, 22, 24] or as a first-step
treatment in patients developing ICH, and not only as a
rescue therapy in the case of refractory ICH [10].
One of the main factors hindering the use of CHT is
safety. Various neurologic complications including seiz-
ure, central pontine myelinolysis, and parenchymal accu-
mulation of osmotic agents have been suspected. We did
not record any neurological alterations that could be re-
lated to CHT, suggesting that it is well-tolerated. How-
ever, we are aware that potential clinical side effects
could be missed in heavily sedated patients.
One of the main fears about the complications of
CHT is hypernatraemia, because it has been associated
with mortality [25, 26]. Hypernatraemia is a common
complication after TBI, in up to 51.5% of patients, even
without CHT, and it is currently impossible to know
from these data if the increased risk of mortality de-
scribed is related to an underlying medical condition or
to hypernatraemia itself. It is of interest to note that only
severe hypernatraemia (> 160 mmol/L) and not moder-
ate hypernatraemia (145–159 mmol/L) is independently
associated with mortality [27]. Close biological monitor-
ing with the measurement of natraemia every 4–12
hours has been shown to enable control of natraemia
within the ranges recommended by international
guidelines (145–155 mmol/L, moderate hypernatremia)
[18, 28] and to reduce the risk of severe hypernatraemia
(Na+ > 160 mmol/L) in < 10% of patients treated with
CHT [10, 21, 24]. Moreover, demonstration that poor
tolerance of dysnatremia is mainly observed in the case
of rapid variations in natraemia [29] provides a strong
rationale to use a continuous infusion adapted to regular
biological follow up rather than repeatable boluses of
hyperosmolar therapy.
Alteration of renal function has also been reported
during CHT [30]. Our results revealed no changes in
urea or creatinine – suggesting no harm to the kidney.
However, Froelich et al. reported a higher risk of patho-
logical creatinine and urea levels in brain-injured pa-
tients receiving CHT without pre-specified biological
monitoring [24]. Taken together, these data underline
the need to set predetermined thresholds for natraemia,
enabling a slow and controlled increase in natraemia
along with close biological monitoring.
This study has several weaknesses. First, this observa-
tional cohort demonstrates an association but not a
causal link between CHT and survival. Second, continu-
ous osmotherapy was performed in one centre, exposing
our results to a centre effect. Even if we found little het-
erogeneity in the estimation of the treatment effects
between the studies included in the meta-analysis,
suggesting that the effect of the treatment is robust to
inter-centre variations in clinical practice, we cannot de-
finitively rule out that other interventions participate in
the better outcomes of patients treated with CHT. Not-
ably, moderate hypocapnia and decompressive craniect-
omy were less frequently used in the group of patients
treated than in patients not treated with CHT. More-
over, the blood electrolyte levels were probably more
frequently measured in the CHT group than in the con-
trol group. A protocol of care with frequent electrolyte
measures could enhance the outcomes of critically ill pa-
tients, as severe dysnatraemia (> 160 mmol/L) is associ-
ated with death [25, 26, 29]. However, protocol-based
control of natraemia was used in the control group, and
no severe dysnatraemia was apparent in this group (see
Fig. 2a). Third, only three randomised trials were avail-
able for the review of literature [22, 31, 32]. We have in-
cluded five before/after studies or quasi-experimental
studies because their study designs provide a good level
of evidence and an accurate estimation of the effect of
the intervention [33]. The results of the systematic re-
view were not significantly changed when only the ran-
domised clinical trials were included. Fourth, the COBI
cohort included patients with moderate to severe TBI
while other studies covered in the systemic review in-
cluded patients with severe brain injury. However, the
heterogeneity between the subgroups (other studies vs.
COBI cohort) for the risk of death was low (I2 = 0%).
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Moreover, the international recommendations on the
methodology of clinical trials, which aimed to improve
the power of neuro-reanimation trials, argue for the use
of inclusion criteria that are as broad as possible, as long
as they are compatible with the mechanisms of action of
the evaluated intervention [34]. Since the secondary oc-
currence of ICH cannot be excluded in patients with
moderate head trauma [35], patients with moderate to
severe head trauma were included in this study. Fifth,
the rate of pupillary abnormalities was higher in the
COBI cohort than in recent studies in patients with
moderate to severe TBI [36]. The COBI cohort included
patients with moderate to severe TBI requiring mechan-
ical ventilation, for whom the GCS scores were fre-
quently quoted early at the trauma scene, and CHT was
administered only in patients with ICH. We therefore
cannot exclude that the recorded GCS score underesti-
mates trauma severity and patients with moderate TBI
were kept in the analysis. Moreover, CHT was adminis-
trated in patients with moderate TBI only in the case of
secondary neurologic deterioration and ICH. Finally, and
despite the very low incidence of side effects recorded in
the present results, it should be noted that our study
was not powered for a description of side effects.
Conclusions
In conclusion, in this large multicentre cohort study, the
use of CHT as a first-tier treatment for ICH was associ-
ated with the increased survival of patients with TBI. This
association was confirmed in a systematic review includ-
ing all available clinical studies. The risk of severe hyper-
natraemia during treatment justifies the setting of
thresholds for acceptable hypernatraemia and adapting
the flow of hyperosmolar therapy to close biological moni-
toring. As advocated by many other authors [21, 24, 37]
and international guidelines [6], a randomised clinical trial
appears to be urgently needed to confirm the effects of
CHT on the outcomes of patients with TBI. To ad-
equately address this issue, we designed the COBI study
(Continuous hyperosmolar therapy for traumatic brain-
injured patients, a multicentre randomised open-label
trial with blinded adjudication of primary outcome –
NCT03143751), which is powered to investigate the ef-
fects of CHT on the neurological outcomes as assessed
by the GOS-Extended at 6 months [38].
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